Intranasal administration of crocetin (100 μM/day, for 9-10 weeks) in OVA-induced asthma in mice, reduced the number of Treg cells and the levels of Foxp3 and TIPE2, indicating treatment properties of crocetin in asthma (195). Here, FOXP3 is linked to asthma.